Canagliflozin vs janagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT01032629 · Phase 3 · completed

The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.

Next expected readout: December 2026 · NCT05427084 (registry estimate)

Reported efficacy

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)

Result source: NCT03170518

janagliflozin · Huiyoujing

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT03811548 · Phase 3 · status unknown

This randomised, double-blind, placebo-controlled Phase 3 trial randomised 432 drug-naive Chinese patients with type 2 diabetes 1:1:1 to placebo or janagliflozin 25 mg or 50 mg. The primary endpoint, HbA1c change at week 24, was met for both doses (placebo-adjusted -0.80% and -0.88%, P<0.001).

432 patients were randomised (publication); the registry's 442 is an estimate on a record not updated since 2020.

Next expected readout: December 2027 · NCT07244003 (registry estimate)

Reported efficacy

Change in HbA1c From Baseline to Week 24 (Baseline and Week 24): Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) (met)

Result source: NCT03811548

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinjanagliflozin
HbA1c, change-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
—Not reported
Body weight, change (kg)-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
—Not reported
HbA1c below 7%42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
—Not reported
Fasting plasma glucose, change-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
—Not reported
3-point MACE (% with event)—Not posted · NCT04304261—Not reported

HbA1c, change

Canagliflozin
-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
janagliflozin
—Not reported

Body weight, change (kg)

Canagliflozin
-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
janagliflozin
—Not reported

HbA1c below 7%

Canagliflozin
42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
janagliflozin
—Not reported

Fasting plasma glucose, change

Canagliflozin
-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
janagliflozin
—Not reported

3-point MACE (% with event)

Canagliflozin
—Not posted · NCT04304261
janagliflozin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

janagliflozin
Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) NCT03811548 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Canagliflozin: 4 of 4 rows · janagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Dropout rate
6.1%300 mga
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
7%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
29%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
0.7%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
1.2%
NCT01989754 · Phase 4 · registry result, not featured evidence
13.2%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02025907 · Phase 4 · registry result, not featured evidence
3.9%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
3.6%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
5.3%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
9.2%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
11%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
10.5%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
5.1%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
24.6%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
23.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
4%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
7.9%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
16.7%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.4%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
8%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
12%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
12.5%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
17.3%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
17.8%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
32.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
14%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
8.6%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
12.5%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
10.9%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
13.8%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
13.3%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
—300 mga
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
—100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT02065791 · Phase 3
—
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—
NCT01989754 · Phase 4 · registry result, not featured evidence
5.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
0.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
1.3%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.3%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
3.4%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
1.7%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
9.7%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
4.4%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0.9%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
7.5%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.1%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
3.1%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
4.7%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
3.1%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
—Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
—Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
Serious AEs
42.1%300 mga
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
41.6%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.7%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.7%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.9%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
33.5%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
17.6%
NCT02920918 · Phase 4 · registry result, not featured evidence
24.6%
NCT01989754 · Phase 4 · registry result, not featured evidence
9.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
7%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
4%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.4%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
3%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
18.2%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.4%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
16.6%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
1.8%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
23.6%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.1%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
20%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
7.1%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.2%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
4.5%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
2.3%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
1%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
6.4%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
3.2%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
0%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.6%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
0%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
300 mga
hypoglycaemia 14.6% (placebo 12.1%)
nasopharyngitis 14.1% (placebo 15.3%)
urinary tract infection 11% (placebo 8.9%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 59 more results
100 mg
nasopharyngitis 15.6% (placebo 15.3%)
hypoglycaemia 12.5% (placebo 12.1%)
upper respiratory tract infection 10.9% (placebo 11.3%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 11.3%
diarrhoea 8%
upper respiratory tract infection 7.8%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 7.6%
diarrhoea 6.8%
upper respiratory tract infection 5.6%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 9.7%
urinary tract infection 9.1%
upper respiratory tract infection 7.5%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 6.8%
back pain 6%
urinary tract infection 5.4%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
urinary tract infection 29.4% (placebo 4.6%)
urinary tract infection 29.4% (placebo 4.6%)
nausea 11.8% (placebo 1.1%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
headache 11.9% (placebo 3.4%)
headache 11.9% (placebo 3.4%)
nasopharyngitis 11.9% (placebo 5.7%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
300 mg
fatigue 3.2%
diarrhoea 1.6%
discomfort 1.6%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 17.6%
hypotensive event 11.8%
arrhythmic events 5.9%
NCT02920918 · Phase 4 · registry result, not featured evidence
balanoposthitis 3.2% (placebo 0.9%)
NCT01989754 · Phase 4 · registry result, not featured evidence
blood glucose decreased 40% (placebo 23.9%)
hypoglycaemia 38.7% (placebo 32.8%)
nasopharyngitis 34.7% (placebo 25.4%)
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
gastroenteritis 9.9%
hypoglycaemia 9.9%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 5.6% (placebo 5.6%)
back pain 2.8% (placebo 0.9%)
depression 2.8% (placebo 0%)
NCT02025907 · Phase 4 · registry result, not featured evidence
blood glucose decreased 26.7% (placebo 16.9%)
hypoglycaemia 25.3% (placebo 21.1%)
nasopharyngitis 16% (placebo 18.3%)
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
300 mg
pollakiuria 5.4% (placebo 1.8%)
nasopharyngitis 0% (placebo 0%)
NCT01939496 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 5.3% (placebo 0%)
pollakiuria 1.8% (placebo 1.8%)
NCT01939496 · Phase 4 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 18.6% (placebo 16.2%)
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 3.8%
upper respiratory tract infection 2.5%
back pain 2.1%
NCT01809327 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 3.8%
glomerular filtration rate decreased 2.5%
influenza 2.5%
NCT01809327 · Phase 3 · registry result, not featured evidence
diarrhoea 4.2%
headache 3%
influenza 3%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 4.2%
headache 3.8%
influenza 3.4%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 18.6% (placebo 15.2%)
hypoglycaemia 15.3% (placebo 19.8%)
urinary tract infection 14.8% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 9.7% (placebo 19.8%)
nasopharyngitis 8.1% (placebo 15.2%)
urinary tract infection 7.2% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 18.7% (placebo 15.2%)
hypoglycaemia 15.4% (placebo 19.8%)
urinary tract infection 13.3% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 10.4% (placebo 19.8%)
nasopharyngitis 9.5% (placebo 15.2%)
influenza 5.8% (placebo 7.6%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 7.5% (placebo 4%)
upper respiratory tract infection 5.7% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 9% (placebo 4%)
upper respiratory tract infection 3.1% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 11.2% (placebo 4.4%)
nasopharyngitis 7.9% (placebo 11.1%)
urinary tract infection 7.9% (placebo 5.6%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 22.5% (placebo 4.4%)
urinary tract infection 13.5% (placebo 5.6%)
nasopharyngitis 10.1% (placebo 11.1%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 14.4% (placebo 4.4%)
arthralgia 4.4% (placebo 2.2%)
bronchitis 4.4% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 20% (placebo 4.4%)
arthralgia 5.6% (placebo 2.2%)
bronchitis 5.6% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 9.6% (placebo 5.2%)
pollakiuria 6.1% (placebo 0.9%)
arthralgia 5.3% (placebo 1.7%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.2% (placebo 5.2%)
arthralgia 7.9% (placebo 1.7%)
urinary tract infection 7.9% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 8% (placebo 6.1%)
back pain 7.1% (placebo 2.6%)
nasopharyngitis 5.3% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 12.4% (placebo 6.1%)
nasopharyngitis 9.7% (placebo 5.2%)
back pain 8.8% (placebo 2.6%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 4.9%
upper respiratory tract infection 4.9%
urinary tract infection 3.5%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.3%
upper respiratory tract infection 6.3%
urinary tract infection 4.6%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
pollakiuria 5.7%
urinary tract infection 4.9%
nasopharyngitis 4.1%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 7.3%
pollakiuria 5.7%
headache 5.2%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.4% (placebo 3.2%)
hypoglycaemia 5.8% (placebo 3.8%)
nasopharyngitis 5.1% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 7.1% (placebo 3.2%)
hypoglycaemia 7.1% (placebo 3.8%)
nasopharyngitis 5.8% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 10.8% (placebo 6.4%)
hypoglycaemia 7% (placebo 3.8%)
urinary tract infection 5.7% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 13.4% (placebo 6.4%)
hypoglycaemia 8.3% (placebo 3.8%)
urinary tract infection 7.6% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 6.8% (placebo 5.2%)
pain in extremity 6.8% (placebo 0%)
urinary tract infection 4.5% (placebo 4.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.1% (placebo 5.2%)
back pain 6.1% (placebo 3.1%)
headache 6.1% (placebo 3.6%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10.2% (placebo 5.2%)
headache 8.6% (placebo 3.6%)
back pain 7.6% (placebo 3.1%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 6.4% (placebo 4.2%)
nasopharyngitis 4.3% (placebo 5.2%)
pain in extremity 2.1% (placebo 0%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 7.2% (placebo 3.6%)
urinary tract infection 7.2% (placebo 4.2%)
nasopharyngitis 5.1% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 9.7% (placebo 3.6%)
urinary tract infection 8.2% (placebo 4.2%)
nasopharyngitis 7.2% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 17.5%
nasopharyngitis 8.8%
upper respiratory tract infection 8.8%
NCT01137812 · Phase 3 · registry result, not featured evidence
300 mg daily
headache 4.7% (placebo 3.1%)
nausea 4.7% (placebo 0%)
abdominal pain upper 3.1% (placebo 1.5%)
NCT00642278 · Phase 2 · registry result, not featured evidence
100 mg daily
headache 7.8% (placebo 3.1%)
urinary tract infection 3.1% (placebo 6.2%)
vulvovaginal mycotic infection 3.1% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
300 mg twice daily
nausea 7.8% (placebo 0%)
abdominal pain upper 6.3% (placebo 1.5%)
urinary tract infection 4.7% (placebo 6.2%)
NCT00642278 · Phase 2 · registry result, not featured evidence
200 mg daily
urinary tract infection 9.2% (placebo 6.2%)
vulvovaginal mycotic infection 6.2% (placebo 0%)
headache 3.1% (placebo 3.1%)
NCT00642278 · Phase 2 · registry result, not featured evidence
50 mg daily
nasopharyngitis 7.8% (placebo 3.1%)
vulvovaginal mycotic infection 6.3% (placebo 0%)
nausea 4.7% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
urinary frequency increased 86.7%
dry mouth 26.7%
light-headedness/dizziness 26.7%
NCT02324842 · Phase na · registry result, not featured evidence
nausea 53.3%
dry mouth 40%
constipation 33.3%
NCT02324842 · Phase na · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 65 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

Albuminuria Progression 18.3% (n=1298) vs 24% (n=1286) placebo @ 338wk300 mg
responder rate · % of participants
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
20.2% (n=1334) vs 24% (n=1286) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
UACR Change 24.47 vs 29.3 placebo mg @ 338wk300 mg
absolute change · mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
25.5 vs 29.3 placebo mg @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.97 vs 43.41 placebo mg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
eGFR -3.98 vs -5.23 placebo mL @ 338wk300 mg
absolute change · mL
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
-3.55 vs -5.23 placebo mL @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
79.9 vs 88.33 placebo mL @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
HbA1c -0.31% (n=1352) vs 0.01% (n=1366) placebo @ 338wk300 mg
absolute change · percentage points
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
-0.93% (n=474) vs -0.81% (n=473) Glimepiride @ 52wk300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.74% (n=474) vs -0.55% (n=474) Glimepiride @ 104wk300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.37% (n=84) vs 0.39% (n=87) placebo @ 26wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.59% (n=84) vs 0.1% (n=83) placebo @ 12wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.32% (n=84) vs 0.7% (n=83) placebo @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-1.42% (n=234) vs -1.3% (n=230) Metformin XR @ 26wk300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-0.73% (n=229) vs -0.03% (n=232) placebo @ 26wk300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-1.06% (n=227) vs -0.47% (n=226) placebo @ 18wk300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
-0.44% (n=89) vs -0.03% (n=87) placebo @ 26wk300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
-1.03% (n=112) vs -0.26% (n=114) placebo @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-0.94% (n=360) vs -0.82% (n=354) Sitagliptin @ 26wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-0.88% (n=360) vs -0.73% (n=354) Sitagliptin @ 52wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-1.06% (n=152) vs -0.13% (n=150) placebo @ 26wk300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-1.03% (n=194) vs 0.14% (n=189) placebo @ 26wk300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-1.03% (n=374) vs -0.66% (n=365) Sitagliptin @ 52wk300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
-0.92% (n=60) vs -0.22% (n=61) placebo @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-0.26% (n=1392) vs 0.01% (n=1366) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.82% (n=478) vs -0.81% (n=473) Glimepiride @ 52wk100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.65% (n=478) vs -0.55% (n=474) Glimepiride @ 104wk100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.37% (n=230) vs -1.3% (n=230) Metformin XR @ 26wk100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-0.6% (n=239) vs -0.03% (n=232) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-0.97% (n=223) vs -0.47% (n=226) placebo @ 18wk100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
-0.33% (n=88) vs -0.03% (n=87) placebo @ 26wk100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
-0.89% (n=113) vs -0.26% (n=114) placebo @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-0.79% (n=365) vs -0.82% (n=354) Sitagliptin @ 26wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-0.73% (n=365) vs -0.73% (n=354) Sitagliptin @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-0.85% (n=155) vs -0.13% (n=150) placebo @ 26wk100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-0.77% (n=191) vs 0.14% (n=189) placebo @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-0.76% (n=62) vs -0.22% (n=61) placebo @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-0.95% (n=62) vs -0.22% (n=61) placebo @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-1.78% (n=236) vs -1.3% (n=230) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-0.7% (n=62) vs -0.22% (n=61) placebo @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-0.61% (n=91) vs -0.01% (n=92) placebo @ 18wk150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-1.77% (n=235) vs -1.3% (n=230) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-0.45% (n=90) vs -0.01% (n=92) placebo @ 18wk50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-0.79% (n=62) vs -0.22% (n=61) placebo @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.85% (n=15) vs 8.26% (n=14) placebo @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
-0.88% (n=76) vs -1.09% (n=67) placebo
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
-0.91% (n=99) vs -0.01% (n=94) placebo @ 26wk
NCT02025907 · Phase 4 · registry result, not featured evidence
-0.97% (n=76) vs 0.13% (n=70) placebo @ 16wk
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
-0.97% (n=70) vs -0.1% (n=68) placebo @ 24wk
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -0.57 vs 0.16 placebo mmol/L @ 338wk300 mg
absolute change · mmol/L
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 34 more results
-1.27 vs -0.38 placebo mmol/L @ 6wk300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-1.13 vs 0.41 placebo mmol/L @ 26wk*300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.3 mg/dL as posted
-0.1 vs -0.02 placebo mmol/L @ 18wk*300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -1.83 mg/dL as posted
-0.65 vs 0.03 placebo mmol/L @ 26wk*300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.7 mg/dL as posted
-1.84 vs 0.14 placebo mmol/L @ 26wk*300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.2 mg/dL as posted
-2.1 vs -1.12 Sitagliptin mmol/L @ 26wk*300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -37.8 mg/dL as posted
-1.95 vs -0.98 Sitagliptin mmol/L @ 52wk*300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -35.2 mg/dL as posted
-1.69 vs 0.23 placebo mmol/L @ 26wk*300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -30.5 mg/dL as posted
-1.94 vs 0.46 placebo mmol/L @ 26wk*300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -35 mg/dL as posted
-1.66 vs -0.32 Sitagliptin mmol/L @ 52wk*300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -29.9 mg/dL as posted
-1.4 vs 0.2 placebo mmol/L @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-0.42 vs 0.16 placebo mmol/L @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.03 vs -0.38 placebo mmol/L @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-1 vs 0.41 placebo mmol/L @ 26wk*100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.1 mg/dL as posted
-0.08 vs -0.02 placebo mmol/L @ 18wk*100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -1.44 mg/dL as posted
-0.83 vs 0.03 placebo mmol/L @ 26wk*100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.9 mg/dL as posted
-1.49 vs 0.14 placebo mmol/L @ 26wk*100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.8 mg/dL as posted
-1.52 vs -1.12 Sitagliptin mmol/L @ 26wk*100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -27.3 mg/dL as posted
-1.45 vs -0.98 Sitagliptin mmol/L @ 52wk*100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.2 mg/dL as posted
-1.01 vs 0.23 placebo mmol/L @ 26wk*100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.2 mg/dL as posted
-1.51 vs 0.46 placebo mmol/L @ 26wk*100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -27.2 mg/dL as posted
-1.4 vs 0.2 placebo mmol/L @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-1.3 vs 0.2 placebo mmol/L @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-1.5 vs 0.2 placebo mmol/L @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-0.88 vs 0.45 placebo mmol/L @ 18wk*150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.9 mg/dL as posted
-0.86 vs 0.45 placebo mmol/L @ 18wk*50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.5 mg/dL as posted
-0.9 vs 0.2 placebo mmol/L @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.93 vs 8.77 placebo mmol/L @ 16wk*
NCT02964585 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 142.79 mg/dL as posted
-1.82 vs -1.84 placebo mmol/L*
NCT02622113 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -32.8 mg/dL as posted
-1.65 vs -0.14 placebo mmol/L @ 26wk
NCT02025907 · Phase 4 · registry result, not featured evidence
-1.89 vs -0.08 placebo mmol/L @ 16wk*
NCT02220920 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -34.1 mg/dL as posted
-1.94 vs 0.22 placebo mmol/L @ 24wk*
NCT02354235 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -34.9 mg/dL as posted
9.66 vs 9.82 Liraglutide mmol/L @ 16wk*
NCT02324842 · Phase na · registry result, not featured evidence · converted to mmol/L from 174 mg/dL as posted
9.99 vs 9.82 Liraglutide mmol/L @ 16wk*
NCT02324842 · Phase na · registry result, not featured evidence · combination · converted to mmol/L from 180 mg/dL as posted
Weight -4.12% (n=1388) vs -0.5% (n=1398) placebo @ 338wk300 mg
percent change · % of baseline
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 33 more results
-4.7% (n=480) vs 1% (n=478) Glimepiride @ 52wk300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.6% (n=84) vs 0% (n=85) placebo @ 26wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.5% (n=84) vs 0.4% (n=85) placebo @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-3.9% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-3.1% (n=229) vs -0.1% (n=234) placebo @ 26wk300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-3.8% (n=112) vs -0.1% (n=114) placebo @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.2% (n=355) Sitagliptin @ 26wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.3% (n=355) Sitagliptin @ 52wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.6% (n=154) vs -0.7% (n=150) placebo @ 26wk300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-3.9% (n=194) vs -0.6% (n=190) placebo @ 26wk300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.5% (n=375) vs 0.3% (n=367) Sitagliptin @ 52wk300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.47% (n=1415) vs -0.5% (n=1398) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-4.2% (n=479) vs 1% (n=478) Glimepiride @ 52wk100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-2.4% (n=240) vs -0.1% (n=234) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-2.8% (n=113) vs -0.1% (n=114) placebo @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-3.7% (n=365) vs -1.2% (n=355) Sitagliptin @ 26wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-3.8% (n=365) vs -1.3% (n=355) Sitagliptin @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.1% (n=156) vs -0.7% (n=150) placebo @ 26wk100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-2.8% (n=192) vs -0.6% (n=190) placebo @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.6% (n=64) vs -1.1% (n=62) placebo @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-4.2% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.7% (n=63) vs -1.1% (n=62) placebo @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.2% (n=91) vs -0.6% (n=92) placebo @ 18wk150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-3.5% (n=237) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.8% (n=90) vs -0.6% (n=92) placebo @ 18wk50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-2.3% (n=63) vs -1.1% (n=62) placebo @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.14% (n=75) vs -1.4% (n=65) placebo
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
-3.35% (n=103) vs -1.6% (n=104) placebo @ 26wk
NCT02025907 · Phase 4 · registry result, not featured evidence
-2.13% (n=75) vs 0.24% (n=70) placebo @ 16wk
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
-3.32% (n=69) vs -0.99% (n=67) placebo @ 24wk
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -11.5 vs 15.3 placebo mg @ 26wk100/300 mg
absolute change · mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
show 1 more result
-16.4 vs 19.2 placebo mg @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 64.9% (n=84) vs 40% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 69% (n=84) vs 29.3% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 51.9% (n=84) vs 27.5% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 54.9% (n=84) vs 22.7% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 41.6% (n=84) vs 11.3% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3

+ 43 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02065791 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.

Next expected readout: December 2026 · NCT05507892 (registry estimate)

Reported efficacy

Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)

Result source: NCT03436693

janagliflozin · Huiyoujing

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2031 · NCT07116928 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinjanagliflozin
Kidney composite outcome—Not reported—Not reported
UACR, % change0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693—Not reported
eGFR slope—Not reported—Not reported
Haemoglobin, change—Not reported—Not reported

Kidney composite outcome

Canagliflozin
—Not reported
janagliflozin
—Not reported

UACR, % change

Canagliflozin
0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693
janagliflozin
—Not reported

eGFR slope

Canagliflozin
—Not reported
janagliflozin
—Not reported

Haemoglobin, change

Canagliflozin
—Not reported
janagliflozin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

janagliflozin: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Canagliflozin: 4 of 4 rows · janagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Dropout rate
0.7%100 mga
NCT02065791 · Phase 3
show 1 more result
19.5%100mg
NCT03436693 · Phase 3
Discontinued due to AEs
—100 mga
NCT02065791 · Phase 3
show 1 more result
14.3%100mg
NCT03436693 · Phase 3
Serious AEs
33.5%100 mga
NCT02065791 · Phase 3
show 1 more result
27.9%100mg
NCT03436693 · Phase 3
Most frequent reported AEs
100 mga
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
show 1 more result
100mg
nasopharyngitis 35.1% (placebo 37%)
hypoglycaemia 21.4% (placebo 20.8%)
blood glucose decreased 17.5% (placebo 14.9%)
NCT03436693 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

eGFR 30% Decline 18.2% (n=154) vs 29.5% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR 40% Decline 10.1% (n=154) vs 13.9% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR Change mL/Min/1.73 m2 -10.39 vs -11.49 placebo mL @ 104wk100mg
absolute change · mL
NCT03436693 · Phase 3
UACR 0.612% (n=124) vs 1.178% (n=127) placebo @ 104wk100mg
percent change · % of baseline
NCT03436693 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · janagliflozin's landscape